文献速递心境障碍

低剂量睾酮辅助治疗女性抗抑郁药耐药重性抑郁:8周随机安慰剂对照研究

Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study.
PubMed 文献 · Am J Psychiatry · 2020-07-14

该8周随机双盲安慰剂对照试验纳入101名21-70岁抗抑郁药耐药重性抑郁女性,评估辅助经皮睾酮对抑郁症状、疲劳和性功能的影响。结果显示睾酮组与安慰剂组MADRS评分均下降但组间无显著差异,疲劳、性功能及副作用亦无差异;fMRI亚组未发现ACC激活差异。

要点

  • 低剂量经皮睾酮辅助治疗未优于安慰剂改善抗抑郁药耐药重性抑郁症状。
  • 疲劳和性功能改善在两组间无显著差异,副作用无差异。
  • fMRI亚组显示睾酮未增加前扣带回皮层激活。

核心结论

  • 辅助经皮睾酮虽耐受良好,但在改善抑郁症状、疲劳或性功能障碍方面不优于安慰剂。

研究设计与样本

  • 8周随机双盲安慰剂对照试验纳入101名21-70岁抗抑郁药耐药重性抑郁女性。
  • fMRI亚组(N=20)主要结局为前扣带回皮层活动变化。

主要发现

  • 睾酮组MADRS从26.8(SD=6.3)降至15.3(SD=9.6),安慰剂组从26.3(SD=5.4)降至14.4(SD=9.3),组间无显著差异。
  • 疲劳和性功能改善组间无差异,副作用无差异。
  • fMRI显示治疗前ACC激活与雄激素水平相关,但睾酮与安慰剂相比ACC激活无差异。

关键数值与推荐

  • 主要结局为MADRS评估的抑郁症状严重程度。
  • 次要终点包括疲劳、性功能和安全性指标。

临床怎么用

  • 不支持低剂量睾酮辅助用于抗抑郁药耐药重性抑郁女性的抑郁症状改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Low-dose testosterone has been shown to improve depression symptom severity, fatigue, and sexual function in small studies in women not formally diagnosed with major depressive disorder. The authors sought to determine whether adjunctive low-dose transdermal testosterone improves depression symptom severity, fatigue, and sexual function in women with antidepressant-resistant major depression. A functional MRI (fMRI) substudy examined effects on activity in the anterior cingulate cortex (ACC), a brain region important in mood regulation. METHODS: The authors conducted an 8-week randomized double-blind placebo-controlled trial of adjunctive testosterone cream in 101 women, ages 21-70, with antidepressant-resistant major depression. The primary outcome measure was depression symptom severity as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS). Secondary endpoints included fatigue, sexual function, and safety measures. The primary outcome of the fMRI substudy (N=20) was change in ACC activity. RESULTS: The participants' mean age was 47 years (SD=14) and their mean baseline MADRS score was 26.6 (SD=5.9). Eighty-seven (86%) participants completed 8 weeks of treatment. MADRS scores decreased in both study arms from baseline to week 8 (testosterone arm: from 26.8 [SD=6.3] to 15.3 [SD=9.6]; placebo arm: from 26.3 [SD=5.4] to 14.4 [SD=9.3]), with no significant difference between groups. Improvement in fatigue and sexual function did not differ between groups, nor did side effects. fMRI results showed a relationship between ACC activation and androgen levels before treatment but no difference in ACC activation with testosterone compared with placebo. CONCLUSIONS: Adjunctive transdermal testosterone, although well tolerated, was not more effective than placebo in improving symptoms of depression, fatigue, or sexual dysfunction. Imaging in a subset of participants demonstrated that testosterone did not result in greater activation of the ACC.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Dichtel LE, Carpenter LL, Nyer M, et al. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study. Am J Psychiatry. 2020. PMID: 32660299. doi:10.1176/appi.ajp.2020.19080844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。